Analyst firms · Leerink Partners · EXAS
Leerink Partners EXAS price target and rating history
Exact Sciences Corporation (EXAS) · Health Care
Leerink Partners rates Exact Sciences Corporation (EXAS) Outperform with a $130 price target, as of its latest action on Feb 23, 2022. It has published 3 rating actions on EXAS since July 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Outperform
- Price target
- $130
- Median target, all firms
- Too few
- Actions on EXAS
- 3
Leerink Partners price target on EXAS
Every Leerink Partners rating on EXAS
- Feb 23, 2022
- Nov 3, 2021
- Jul 14, 2021
How other firms rate EXAS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Mizuho | Neutral | $105 | Jan 20, 2026 |
| Evercore ISI | In-line | $105 | Jan 5, 2026 |
Questions about Leerink Partners and EXAS
- What is Leerink Partners's price target for EXAS?
- Leerink Partners's latest stated price target for Exact Sciences Corporation (EXAS) is $130, from its action on Feb 23, 2022.
- What is Leerink Partners's rating on EXAS?
- Leerink Partners rates EXAS Outperform, a bullish rating, as of Feb 23, 2022.
- When did Leerink Partners last change its view on EXAS?
- On Feb 23, 2022, Leerink Partners cuts its price target to $130 from $140, keeps Outperform.
More EXAS rating histories
All Leerink Partners ratingsEXAS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.